Of particular concern to physicians and other health care professionals is the fact that the number of prescriptions written in the United States to treat yeast infections has almost doubled between 1980 and 1990, reaching 13 million. Statistical data derived from patients treated at genitourinary medicine centers in the United Kingdom indicate a similarly sharp increase, from 118/100,000 to 200/ 100,000 patients during the last decade. Moreover, although the causative organism in 85-90% of all cases of VVC is Candida albicans, some evidence suggests that the proportion of non-albicans Candida infections, including those caused by C. (Torulopsis) glabrata, C. tropicalis, and C. krusei, is rising substantially. 2'5 Traditional imidazole treatment regimens have often shown less efficacy against those species than against most of the approximately 200 known pathogenic strains of C.
albicans. 1, 6, 7 Amid these causes for concern, however, positive developments are the number of therapeutic agents and range of treatment options available for the management of VVC. Most women with acute VVC can be treated with short-term regimens that are likely to enhance compliance and thus minimize the risk of treatment failure. 2'8'9 Newer triazole suggested by a cross-sectional observational study conducted over a 12-week period at an urban hospital in Australia. 23 Of 7 6 patients receiving fluconazole, 3 5 had been prescribed potentially interacting drugs and 9 of those patients were judged to have experienced 10 possible adverse interactions.
In patient who received concomitant cyclosporine and fluconazole, the cyclosporine plasma concentration rose from 7 53 ng/ml to 1,543 ng/ml after 6 days of combination therapy. Potential adverse reactions also occurred in patients receiving fluconazole in conjunction with the following drugs: warfarin (2 of 4 patients), theophylline (1 of 2), phenytoin (3 of 9), rifabutin (2 of 4), and rifampin (1 orS). 
